Beyond quadruple therapy: the potential roles for ivabradine, vericiguat, and omecamtiv mecarbil in the therapeutic armamentarium-Reference-Cited by-同舟云学术

Beyond quadruple therapy: the potential roles for ivabradine, vericiguat, and omecamtiv mecarbil in the therapeutic armamentarium

Published:2024-06-29 Issue:5 Volume:29 Page:949-955
ISSN:1573-7322
Container-title:Heart Failure Reviews
language:en
Short-container-title:Heart Fail Rev

Author:

Shoji Satoshi^ORCID,Mentz Robert J.

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s10741-024-10412-y.pdf

Reference42 articles.

1. Heidenreich PA, Bozkurt B, Aguilar D et al (2022) 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. https://www.ahajournals.org/doi/10.1161/CIR.0000000000001063

2. McDonagh TA, Metra M, Adamo M et al (2021) 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 42:3599–3726. https://doi.org/10.1093/eurheartj/ehab368

3. Mebazaa A, Davison B, Chioncel O et al (2022) Safety, tolerability, and efficacy of up-titration of guideline- directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial. Lancet 400:1938–1952. https://doi.org/10.1016/S0140-6736(22)02076-1

4. McDonagh TA, Metra M, Adamo M et al (2023) 2023 Focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 37:2129–2200. https://doi.org/10.1093/eurheartj/ehad195

5. Psotka MA, Teerlink JR (2016) Ivabradine: role in the chronic heart failure armamentarium. Circulation 133:2066–2075. https://doi.org/10.1161/CIRCULATIONAHA.115.018094